<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE339nnn/GSE339309/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339309</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Thymic age and peripheral residence time determine anti-tumor competence of CD8+ T cells</name><description>The developmental timing of T cell generation imprints durable functional programs, yet how this shapes anti-tumor immunity remains unclear. Here, we combine genetic fate mapping with functional assays to dissect how thymic age and peripheral residency regulate CD8⁺ T cell behaviour within the same host. We find that, compared with adulthood-derived CD8⁺ T cells, the adolescent-derived counterparts consistently exhibit enhanced tumor infiltration, increased effector cytokine production, and superior proliferative fitness. Transcriptomic and phenotypic profiling identify a CXCR3⁺IL-18Rα⁺ subset preferentially enriched among adolescent-derived T cells that shares core virtual memory-like features and displays elevated cytotoxic potential. Mechanistically, thymic origin timing and time spent in the periphery independently regulate the abundance and activity of this subset, revealing a two-tier control comprising developmental bias and post-thymic remodelling. Functionally, CXCR3⁺IL-18Rα⁺ CD8⁺ T cells mediate potent tumor killing and confer robust therapeutic benefit in adoptive transfer models. Together, these findings establish developmental imprinting as an important determinant of CD8⁺ T cell heterogeneity and identify CXCR3⁺IL-18Rα⁺ CD8⁺ T cells as key effectors for anti-tumor immunity.</description><dates><publication>2026/09/01</publication></dates><accession>GSE339309</accession><cross_references><GSM>GSM9893329</GSM><GSM>GSM9893327</GSM><GSM>GSM9893328</GSM><GSM>GSM9893325</GSM><GSM>GSM9893326</GSM><GSM>GSM9893323</GSM><GSM>GSM9893324</GSM><GSM>GSM9893322</GSM><GPL>30172</GPL><GSE>339309</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>